| First Author | Guarda G | Year | 2011 |
| Journal | Immunity | Volume | 34 |
| Issue | 2 | Pages | 213-23 |
| PubMed ID | 21349431 | Mgi Jnum | J:168972 |
| Mgi Id | MGI:4939502 | Doi | 10.1016/j.immuni.2011.02.006 |
| Citation | Guarda G, et al. (2011) Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34(2):213-23 |
| abstractText | Type I interferon (IFN) is a common therapy for autoimmune and inflammatory disorders, yet the mechanisms of action are largely unknown. Here we showed that type I IFN inhibited interleukin-1 (IL-1) production through two distinct mechanisms. Type I IFN signaling, via the STAT1 transcription factor, repressed the activity of the NLRP1 and NLRP3 inflammasomes, thereby suppressing caspase-1-dependent IL-1beta maturation. In addition, type I IFN induced IL-10 in a STAT1-dependent manner; autocrine IL-10 then signaled via STAT3 to reduce the abundance of pro-IL-1alpha and pro-IL-1beta. In vivo, poly(I:C)-induced type I IFN diminished IL-1beta production in response to alum and Candida albicans, thus increasing susceptibility to this fungal pathogen. Importantly, monocytes from multiple sclerosis patients undergoing IFN-beta treatment produced substantially less IL-1beta than monocytes derived from healthy donors. Our findings may thus explain the effectiveness of type I IFN in the treatment of inflammatory diseases but also the observed 'weakening' of the immune system after viral infection. |
